• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ocugen, Inc. - Common Stock (NQ:OCGN)

    1.595 +0.004 (+0.28%)
    Streaming Delayed Price Updated: 1:49 PM EST, Jan 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,956,591
    Open 1.600
    Bid (Size) 1.590 (27,000)
    Ask (Size) 1.600 (9,100)
    Prev. Close 1.590
    Today's Range 1.570 - 1.650
    52wk Range 0.5150 - 1.960
    Shares Outstanding 257,328,085
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
    From Ocugen
    Via GlobeNewswire

    Performance

    YTD
    +15.5%
    +15.5%
    1 Month
    +7.7%
    +7.7%
    3 Month
    +2.2%
    +2.2%
    6 Month
    +54.8%
    +54.8%
    1 Year
    +118.1%
    +118.1%

    More News

    Read More
    News headline image
    Ocugen Stock Is Surging Today: What's Driving The Action? ↗
    Via Benzinga
    News headline image
    Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
    From Ocugen
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 5, 2025 ↗
    Via Benzinga
    News headline image
    Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
    From Ocugen
    Via GlobeNewswire
    News headline image
    OCGN Stock Rises Pre-Market After Gene Therapy Data Shows Promise In Rare Eye Disorder ↗
    Via Stocktwits
    News headline image
    Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen (OCGN) Q3 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    OCUGEN INC (NASDAQ:OCGN) Reports Mixed Q3 2025 Results Amid Clinical Pipeline Progress ↗
    Via Chartmill
    News headline image
    Ocugen Provides Business Update with Third Quarter 2025 Financial Results
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen to Present at Industry and Investor Conferences in October 2025
    From Ocugen
    Via GlobeNewswire
    News headline image
    Forecasting The Future: 4 Analyst Projections For Ocugen ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
    Via Benzinga
    News headline image
    Why Ocugen Stock Zoomed 12% Higher Today ↗
    Via The Motley Fool
    News headline image
    Ocugen Shares Are Trading Higher Monday: What's Going On? ↗
    Via Benzinga
    News headline image
    Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
    From Ocugen
    Via GlobeNewswire
    News headline image
    Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
    From Ocugen
    Via GlobeNewswire

    Frequently Asked Questions

    Is Ocugen, Inc. - Common Stock publicly traded?
    Yes, Ocugen, Inc. - Common Stock is publicly traded.
    What exchange does Ocugen, Inc. - Common Stock trade on?
    Ocugen, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Ocugen, Inc. - Common Stock?
    The ticker symbol for Ocugen, Inc. - Common Stock is OCGN on the Nasdaq Stock Market
    What is the current price of Ocugen, Inc. - Common Stock?
    The current price of Ocugen, Inc. - Common Stock is 1.595
    When was Ocugen, Inc. - Common Stock last traded?
    The last trade of Ocugen, Inc. - Common Stock was at 01/27/26 01:49 PM ET
    What is the market capitalization of Ocugen, Inc. - Common Stock?
    The market capitalization of Ocugen, Inc. - Common Stock is 410.31M
    How many shares of Ocugen, Inc. - Common Stock are outstanding?
    Ocugen, Inc. - Common Stock has 410M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.